{
    "name": "sodium hyaluronate",
    "comment": "Rx",
    "other_names": [
        "Amvisc",
        "Hyalgan",
        "Amvisc Plus",
        "Euflexxa",
        "Healon",
        "Healon GV",
        "Healon5",
        "Supartz",
        "Gelsyn-3",
        "Durolane",
        "TriVisc",
        "Triluron"
    ],
    "classes": [
        "Intra-Articular Agents",
        "Ophthalmics",
        "Other",
        "Rheumatologics",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/amvisc-hyalgan-sodium-hyaluronate-343375",
    "pregnancy": {
        "common": [
            "Teratogenic Effects- Reproductive toxicity studies, including multigeneration studies, performed in rats and rabbits at doses up to 11 times the anticipated human dose (1.43 mg/kg per treatment cycle) have revealed no evidence of impaired fertility or harm to experimental animal fetus due to intra-articular injections of this drug",
            "Animal reproduction studies are not always predictive of human response; safety and effectiveness of this drug have not been established in pregnant women"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "It is not known if this drug is excreted in human milk; safety and effectiveness have not been established in lactating women"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Intra-articular use",
                    "description": [
                        "Pain relief may not be evident until after 3rd injection",
                        "If infections or skin diseases present in the area of injection site may develop septic arthritis",
                        "Not for use concomitantly with disinfectants containing quaternary ammonium salts for skin preparation; hyaluronic acid can precipitate in their presence",
                        "Anaphylactoid and allergic reactions reported with this product",
                        "Transient increases in inflammation in the injected knee following injection in some patients with inflammatory arthritis such as rheumatoid arthritis or gouty arthritis reported",
                        "Patients should be carefully examined prior to administration to determine signs of acute inflammation; physician should evaluate whether treatment should be initiated when objective signs of inflammation are present",
                        "Effectiveness of single treatment cycle of less than 3 injections not established",
                        "Safety and effectiveness of use in joints other than knee not established",
                        "Safety and effectiveness of use of this product concomitantly with other intra-articular injectables not established",
                        "Use caution when injecting product into patients who are allergic to avian proteins, feathers, and egg products",
                        "As with any invasive joint procedure, recommended that patient avoid any strenuous activities or prolonged (eg, more than 1 hour) weight-bearing activities such as jogging or tennis within 48 hours following the intra-articular injection"
                    ]
                },
                {
                    "type": "Ophthalmic use",
                    "description": [
                        "Use only if solution is clear",
                        "Monitor intraocular pressure",
                        "Tell all health care providers about (hyaluronate and derivatives injection (eye)), including doctors, nurses, pharmacists, and dentists",
                        "Inform doctor if pregnant, plan on getting pregnant, or are breast-feeding; discuss with doctor about benefits and risks for patient and the baby"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Erythema",
            "percent": "75-93"
        },
        {
            "name": "Swelling",
            "percent": "91-03"
        },
        {
            "name": "Tenderness",
            "percent": "61-92"
        },
        {
            "name": "Lumps",
            "percent": "56-83"
        },
        {
            "name": "bumps",
            "percent": "33-78"
        },
        {
            "name": "Discoloration",
            "percent": "25-36"
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Injection site pain",
            "percent": null
        },
        {
            "name": "Anaphylactoid reaction",
            "percent": null
        },
        {
            "name": "Increased IOP",
            "percent": null
        },
        {
            "name": "Keratitis",
            "percent": null
        },
        {
            "name": "Cystoid macular edema",
            "percent": null
        },
        {
            "name": "Conjunctival hemorrhage",
            "percent": null
        }
    ]
}